

General Information

- ◆ Approved in FY 2018
- ◆ Established in September 2019
- ◆ Established by the Graduate School of Medicine
- ◆ Partner institution: The University of California San Diego (UCSD), USA
- ◆ Location: The University of California San Diego (UCSD), San Diego, USA (outbound)
- ◆ Purposes: Acceleration of research collaboration, industry-academia collaboration, education collaboration, and global human resource development through sharing space in the Center for Novel Therapeutics with UCSD's top researchers
- ◆ Functions: Joint research in the field of medicine and expansion of collaboration with academic institutions and industrial partners in San Diego.


Positive ripple effects on the university's activities

- Promotion of international joint research
- Support for study abroad and global exchange by students and faculty and staff members
- Recruitment of talented international students and researchers
- Support for KU ventures

【FY 2025】

- The UCSD School of Medicine campus, where KURC-SD is located, is home to several prominent research institutions, including the Moores Cancer Center and the La Jolla Institute for Immunology (LJI), and hosts numerous world-renowned researchers in the field of immunology. Leveraging this environment, a collaborative research program focused on human immunology is being launched, with preparations underway for joint grant applications to organizations such as the NIH. This initiative is expected to drive cutting-edge research and strengthen collaboration with Kyoto University.
- KURC-SD will serve as an open-space research environment, offering Kyoto University researchers a cost-effective and convenient setting to initiate new projects.

Activity Overview



Main Activities in FY 2024

① 6th Kyoto University LifeScience Showcase (KULS) @San Diego 2025 (February 20–21, 2025)

- A pitch event was held in San Diego with the aim of promoting the international dissemination of innovations in medical fields by Kyoto University and other institutions.
- Eleven domestic and international startup companies involved in medical device and drug discovery development took the stage, joined by eleven expert commentators with experience in launching businesses in the US. A total of 104 participants attended, including venture capitalists, investors, and representatives from pharmaceutical companies. During the reception following the pitch event, active information exchange and preliminary business discussions took place between the presenting companies and attendees.
- On February 21, an educational seminar was held for the companies participating in the pitch event, featuring lectures on launching businesses in the United States by lawyers, accountants, and investors based in San Diego.



② Other notable achievements

- To advance international research collaboration on human immunology using KURC-SD as a base, discussions have begun to conclude a comprehensive collaboration agreement with UC San Diego, La Jolla Institute for Immunology (LJI), and Chiba University, all of which utilize the AMED-SCARDA initiative.
- A startup originating from Kyoto University, which participated in the KULS in the past, leveraged the connections built through the event to advance clinical trials of its product in the United States. With support from the AMED, the company relocated its headquarters to the US and expanded its business operations.
- Utilizing the network developed through the OSL, a clinical trial is currently underway to treat Parkinson's disease using transplants of nerve cells created from human iPS cells.